Carisma Therapeutics, Inc.
CARM
$0.2153
$0.00180.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -14.83% | -11.55% | 158.34% | 4.75% | 14.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -14.83% | -11.55% | 158.34% | 4.75% | 14.96% |
| Cost of Revenue | -19.76% | -42.07% | -17.34% | 4.93% | 7.37% |
| Gross Profit | 21.16% | 49.50% | 59.15% | -4.98% | -5.40% |
| SG&A Expenses | -46.34% | -21.40% | -7.44% | -43.13% | 654.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.04% | -36.84% | -14.92% | -12.62% | 40.34% |
| Operating Income | 29.38% | 41.17% | 44.34% | 15.07% | -46.52% |
| Income Before Tax | 16.64% | 40.65% | 43.59% | 22.64% | -26.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 15.86% | 40.65% | 43.84% | 22.99% | -25.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.86% | 40.65% | 43.84% | 22.99% | -25.20% |
| EBIT | 29.38% | 41.17% | 44.34% | 15.07% | -46.52% |
| EBITDA | 30.11% | 42.69% | 43.63% | 19.98% | -48.65% |
| EPS Basic | 18.60% | 42.52% | 45.57% | 75.95% | 93.18% |
| Normalized Basic EPS | 28.51% | 42.50% | 45.35% | 75.85% | 93.12% |
| EPS Diluted | 18.60% | 42.52% | 45.57% | 75.95% | 93.18% |
| Normalized Diluted EPS | 28.51% | 42.50% | 45.35% | 75.85% | 93.12% |
| Average Basic Shares Outstanding | 3.37% | 3.23% | 3.19% | 220.24% | 1,735.98% |
| Average Diluted Shares Outstanding | 3.37% | 3.23% | 3.19% | 220.24% | 1,735.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |